From Guidelines to Clinical Practice: Expert Perspectives on Long‐Term Management of Obesity
Obesity · 2026
DOI: 10.1002/oby.70263 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Obesity, 2026. Verfasst von Hong Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Zhujiang Hospital of Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Obesity, Anti-Obesity Agents, Practice Guidelines as Topic. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly China.
Abstract (Originalsprache)
An international panel of experts from the U.S. and China convened to discuss the 2026 TOS–OMA–OAC Expert Guidance Statement on the Pharmacological Management of Obesity, focusing on emerging evidence, regional considerations, and challenges in translating recommendations into long‐term care. Panelists reached a consensus that obesity should be recognized as a chronic and progressive disease, for which pharmacotherapy is lifelong once initiated, as discontinuation consistently leads to weight regain and loss of metabolic benefit. The discussion highlighted a shift toward treating obesity itself as an upstream intervention capable of modifying multiple obesity‐related complications, with greater weight loss generally conferring greater clinical benefit. Visceral adipose tissue emerged as a particularly relevant therapeutic target, especially in Asian populations, where substantial metabolic risk may be present at lower BMI levels. Panelists noted heterogeneity in treatment response and that eventual weight‐loss plateaus should be anticipated as evidence of maximal effectiveness rather than medication failure. The panel endorsed an individualized, stepwise approach integrating pharmacotherapy and metabolic surgery as complementary strategies. Finally, the panel emphasized that translating therapeutic advances into real‐world benefit will require addressing practical barriers related to policy, access, affordability, and stigma to ensure effective care reaches those who need it most.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhujiang Hospital of Southern Medical University, Guangzhou, China.
- Zhongda Hospital, Southeast University, Nanjing, China.
- Peking University First Hospital, Beijing, China.
- Division Endocrinology, Diabetes and Metabolic Diseases, Department of Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.
- Division of Endocrinology, Diabetes & Metabolic Diseases, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
- Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
Förderung
- Eli Lilly China
Zitieren
APA
Chen, H., Li, L., Zhang, J., Zhu, S., Cornier, M. A., & Purnell, J. Q. (2026). From Guidelines to Clinical Practice: Expert Perspectives on Long‐Term Management of Obesity. Obesity. https://doi.org/10.1002/oby.70263
Vancouver
Chen H, Li L, Zhang J, Zhu S, Cornier MA, Purnell JQ. From Guidelines to Clinical Practice: Expert Perspectives on Long‐Term Management of Obesity. Obesity. 2026. doi:10.1002/oby.70263
BibTeX
@article{Chen2026,
author = {Chen, Hong and Li, Ling and Zhang, Junqing and Zhu, Shaihong and Cornier, Marc-André and Purnell, Jonathan Q},
title = {From Guidelines to Clinical Practice: Expert Perspectives on Long‐Term Management of Obesity},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70263}
}
EUVIMED